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Racial Disparities on the Use of Invasive and Noninvasive
Staging in Patients with Non-small Cell Lung Cancer
Jennifer Marie Suga, MD, MPH,* Danh V. Nguyen, PhD,† Sandra M. Mohammed, MS,†
Monica Brown, PhD,‡ Royce Calhoun, MD,* Ken Yoneda, MD,§ David R. Gandara, MD,*
and Primo N. Lara, Jr., MD*
Introduction: Racial disparities have been reported in non-small
cell lung cancer (NSCLC) staging and therapeutic outcomes. We
investigated whether such disparities exist in the era of modern
noninvasive staging modalities, including positron emission tomog-
raphy scan use.
Methods: NSCLC patients from the California Cancer Registry
diagnosed between January 1, 1994, and December 31, 2004, were
included. The likelihood of obtaining invasive (thoracoscopy,
bronchoscopy, and mediastinoscopy) and noninvasive staging
procedures (computed tomography, magnetic resonance imaging,
and positron emission tomography scans), along with surgical
resection, were analyzed using logistic regression adjusted for
known confounders.
Results: Of 13,762 NSCLC patients, 12,395 with adequate staging
information were included. 10,217 patients (82%) were classified as
white, 2178 patients (18%) were non-white, and 738 were black
patients (6%). No association was seen between race and the use of
either noninvasive (odds ratio [OR]  1.02; p  0.76) or invasive
staging procedures (OR  0.96; p  0.44). However, compared
with white patients, black patients had a lower likelihood of under-
going surgery, regardless of noninvasive (OR  0.6; p 0.001) or
invasive staging use (OR  0.63; p  0.02). There was no survival
difference for those who underwent surgery between white and
non-white patients, regardless of noninvasive (hazard ratio  0.95;
p  0.45) or invasive staging (hazard ratio  1.03; p  0.79).
Conclusions: In contrast to prior published work, we found no
difference in rates of both invasive and noninvasive staging between
white and non-white patients. However, non-white patients—partic-
ularly blacks—were less likely to receive surgery. The reason for the
apparent difference in surgical rates could not be explained by the
variables we evaluated. Thus, other factors such as personal prefer-
ence or access to care require further investigation.
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Lung cancer is considered a public health hazard and hasbeen the leading cause of cancer-related death in the
United States for decades. Non-small cell lung cancer
(NSCLC) is the most common subtype, accounting for ap-
proximately 85% of all cases. Published reports investigating
racial differences in cancer epidemiology have revealed that
black patients have a higher mortality rate compared with
whites in several malignancies, including lung, breast, colon,
and prostate cancers.1–3
Several factors potentially contribute to the racial dispar-
ities related to lung cancer diagnosis and management. Difficul-
ties with access to care can result in black patients presenting at
a more advanced stage compared with non-black patients.4,5
Other factors include quality of care after diagnosis,6 noncancer-
related comorbid conditions,7 and socioeconomic factors,8
which may influence treatment decisions.
There is controversy whether race independently af-
fects patient outcomes. Previous studies have suggested an
association between race and the likelihood of undergoing
surgery for resectable NSCLC.9–11 In 1998, Greenwald et
al.11 published analysis of the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) data-
base from three regions (Detroit, San Francisco, and Seattle)
that reported whites being 20% more likely to undergo
surgery than blacks and 31% more likely to survive 5 years.
Bach et al.9 subsequently presented further analysis of the
SEER database and reported that after accounting for con-
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founding factors including coexisting illness, socioeconomic
status (SES), insurance, and availability of care, blacks were
12.7% less likely than whites to undergo surgical resection.
Five-year survival rate was also lower for blacks (26 versus
34%; p  0.001).
Proper staging is crucial for patients who are diagnosed
with lung cancer to deliver an accurate prognosis and deter-
mine further treatment recommendations. Lathan et al. exam-
ined the SEER database to determine whether race impacted
invasive staging including mediastinoscopy, bronchoscopy,
and thoracoscopy. These investigators reported that black
patients were less likely to undergo invasive staging and,
even once properly staged, were still less likely to undergo
surgery.12
It is currently unknown whether there are any racial
disparities in obtaining noninvasive tests for staging. In
particular, the use of positron emission tomography (PET)
scan has increased significantly in the last several years.
Previous work from our group showed an increased use of
PET scan from 6.5% in 1994–1998 to 20.1% in 1999–2004,
which was associated with fewer patients with stage III
disease but more patients with stage IV disease during those
two periods.13 It is unclear whether this increase is seen in all
patients regardless of race and whether the additional staging
information provided by PET scans influence the decision of
whether surgery is performed.
Therefore, we sought to define the frequency of obtain-
ing both invasive and noninvasive staging stratified by race
and determine whether race is an independent predictor for
undergoing surgical resection for newly diagnosed NSCLC.
PATIENTS AND METHODS
Data were obtained from the California Cancer Regis-
try (CCR), a state-wide population-based cancer surveillance
system composed of eight regional registries collecting can-
cer incidence and mortality information since 1988. Cases are
reported to the Cancer Surveillance Section of the California
Department of Public Health from hospitals and any other
facilities providing care or therapy to cancer patients residing
in California.14 Cases included in these analyses were inva-
sive NSCLC diagnosed between January 1, 1994, and De-
cember 31, 2004, and reported to the Cancer Surveillance
Program, the Sacramento Region or Region 3 of the CCR as
of October 2006. NSCLC was defined using International
Classification of Diseases for Oncology second and third
edition site codes C34.0–C34.9 and histology codes, 8004,
8010, 8012, 8013, 8020–8022, 8031–8033, 8046, 8070–
8076, 8082–8084, 8123, 8140, 8145, 8230, 8249–8253,
8255, 8260, 8310, 8430, 8550, 8560, 8574, and 8720.15,16
Race/ethnicity was based on information obtained from
the medical record, which can be derived from patient self-
identification; assumptions based on personal appearance; or
inferences based on the race/ethnicity of the parents, birth-
place, surname, or maiden name. Hispanic ethnicity was
based on information from the medical record and comput-
erized comparisons with the 1980 U.S. census list of Hispanic
surnames. Patients identified as Hispanic on the medical
record or patients identified as white, black, or of unknown
race with a Hispanic surname were classified as Hispanic.
SES and rural/urban designation were assigned at the
Census block group level (2000 U.S. Census) and based on
the address at the time of initial diagnosis as reported in the
medical record. This SES variable is an index that uses
education, employment characteristics, median household in-
come, proportion of the population living 200% below the
federal poverty level, median rent, and median housing value
of census tract of residence for case and denominator popu-
lation. A principal components analysis was used to identify
quintiles of SES ranging from 1 (lowest) to 5 (highest).17
Rural/urban designation was defined by Rural Urban Com-
muting Area codes developed and categorized by the Univer-
sity of Washington’s Rural Health Research Center.18
Stage at diagnosis was collected from the patient’s
medical record and coded according to the American Joint
Commission on Cancer Staging Manual, Sixth Edition.19
Stage determination was based on information after all stag-
ing procedures were completed. Text fields pertaining to
x-rays, scoping procedures, and any additional remarks were
extracted from the CCR’s data management system. A com-
puter program was developed specifically to search, identify,
and code all keywords and synonyms implicit of an imaging
procedure.20 Chest x-ray, CT scan, magnetic resonance im-
aging (MRI), PET scan, mediastinoscopy, bronchoscopy,
thoracoscopy, and radiofrequency ablation were coded as
“done” or “not done” based on the presence or lack of
keywords or phrases within the extracted text fields. Cases
that could not be assigned values based on keyword coding
were manually reviewed.
This study was reviewed and approved by the appro-
priate Institutional Review Boards at UC Davis and the CCR.
Statistical Analysis
Differences in the distribution of noninvasive (PET,
MRI, and CT scan) and invasive (mediastinoscopy, bronchos-
copy, and thoracoscopy) staging procedure use, age at diag-
nosis, sex, residence type (urban or rural), disease stage,
surgery type, radiation, and chemotherapy between white and
non-white patients were evaluated using the t test for contin-
uous variables and 2 testing for proportions. Logistic regres-
sion models were used to evaluate the likelihood (odds) of
noninvasive (and similarly for invasive) staging procedure
adjusted for known confounders. Similarly, logistic regres-
sion was used to evaluate the odds of receiving surgery
among staged patients. The “any invasive” group include
patients who also could have received noninvasive proce-
dures, just as the “any noninvasive” group include patients
who have received invasive procedures. SES score repre-
sented quintiles (1  low to 5  high) and was modeled as
a continuous variable; therefore, the odds ratio (OR) reported
corresponds to a quintile change. Comparison of survival
between white and non-white patients was based on the
Kaplan-Meier method,21 and log-rank statistic was used for
the comparison of overall survival distributions.22 Cox re-
gression analysis23 was used to obtain adjusted hazard ratios
for death for non-white and white groups. In our secondary
analyses, we repeated the above described analyses to eval-
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uate the likelihood of staging type, surgery, and survival with
race categorized as white, black, and other. All analyses were
performed using SAS 9.2 (SAS Institute Inc., Cary, NC). All
p values reported are for two-sided tests.
RESULTS
Patient Characteristics
There were 13,762 patients with NSCLC identified
from the CCR. The study cohort includes a total of 12,395
patients who had adequate staging information (stage I–IV).
The cohort consisted of 10,217 (83%) white and 2178 (17%)
non-white patients. The non-white group comprised 738
patients classified as non-Hispanic black (6%), 736 (5.9%)
Hispanic patients, 667 (5.4%) Asian/Pacific Islander patients,
and the 37 (0.3%) remaining were classified as non-Hispanic
American Indian or other/unknown patients.
Table 1 summarizes characteristics for all patients by
race. White patients had an older mean age compared with
non-whites as well as had higher SES levels. More non-white
patients resided in urban areas compared with white patients.
More white patients had stages I and II disease, whereas more
non-white patients had stages III and IV disease. More white
patients underwent surgery, whereas more non-white patients
received chemotherapy.
Table 1 also summarizes the use of noninvasive and
invasive staging procedures stratified by race. There was no
difference between the two groups with respect to noninva-
sive or invasive staging. Eight patients with missing resi-
dence type data were excluded from subsequent analyses.
Likelihood of Noninvasive and Invasive Staging
Procedures
The likelihood (odds) of patients obtaining any nonin-
vasive staging procedures (PET, CT, or MRI use) or invasive
staging procedures (bronchoscopy, thoracoscopy, or medias-
tinoscopy) was determined using logistic regression control-
ling for confounders. There was no difference in the odds of
obtaining noninvasive staging procedure between non-white
and white patients: OR was 1.02 (95% CI: 0.89–1.2; p 
0.76). Similarly, race did not affect the likelihood of obtain-
ing invasive staging procedures: OR was 0.96 (95% CI:
0.87–1.06; p  0.44). Table 2 summarizes the results of
obtaining any noninvasive and invasive staging procedure.
Table 3 focuses on the odds of obtaining specific
staging procedures. Table 3 summarizes the odds of obtaining
a PET, MRI, or CT scan. PET use OR (non-white to white)
was 0.98 (95% CI: 0.85–1.12; p  0.72); MRI use OR was
0.80 (95% CI: 0.63–1.01; p 0.06); and CT use OR was 1.05
(95% CI: 0.91–1.21; p 0.50). Male patients were associated
with lower chance of using PET scan (p 0.01), and a higher
SES was significantly associated with increased likelihood of
obtaining a PET scan (p  0.0001). Residence type (rural/
urban area) did not affect the likelihood of having a nonin-
vasive staging procedure. Stage II patients were more likely
TABLE 1. Patient Characteristics by Race
Characteristics
Nonwhite
Patients
(n  2178)
White
Patients
(n  10,217) p
Age, mean (range) 65.7 (22–95) 68.3 (21–100) 0.001
Sex (%)
Male 1252 (58) 5548 (54) 0.007
SES (%)
Lowest quartile 577 (27) 1228 (12) 0.001
Highest quartile 120 (6) 764 (8)
Disease stage (%)
Stage I 382 (18) 2219 (22) 0.001
Stage II 66 (3) 452 (4)
Stage III 715 (33) 3130 (31)
Stage IV 1015 (47) 4416 (43)
Residence (%)
Urban 2060a (95) 8679a (85) 0.001
Staging procedureb (%)
CT scan 1900 (87) 8866 (87) 0.57
MRI 92 (4) 475 (5) 0.39
PET scan 291 (13) 1517 (15) 0.07
Bronchoscopy 879 (40) 4005 (39) 0.32
Mediastinoscopy 63 (3) 337 (3) 0.33
Thoracoscopy 11 (0.5) 57 (0.6) 0.76
Type of treatmentb (%)
Lobectomy/partial
pneumonectomy
442 (20) 2542 (25) 0.001
Pneumonectomy 41 (2) 280 (3)
Lung surgery, NOS 5 (0.2) 52 (0.5)
None or unknown 1690 (78) 7343 (72)
Radiation 933 (43) 4312 (42) 0.59
Chemotherapy 795 (37) 3374 (33) 0.002
a Denominator is reduced by 2 and 8 for non-white and white patients, respectively.
b Total greater than column denominator because a patient can have multiple
staging procedure/treatment.
SES, socioeconomic status; CT scan, computed tomography scan; MRI, magnetic
resonance imaging; PET scan, positron emission tomography scan; NOS, not otherwise
specified.
TABLE 2. Predictors of Undergoing Noninvasive and
Invasive Staging Procedures
Any
Noninvasivea
Any
Invasiveb
OR p OR p
Race 1.02 0.76 0.96 0.44
Nonwhite (reference  white)
Age 1 0.23 0.99 0.0001
Sex
Male (reference  female) 1.02 0.8 1.22 0.0001
Residence
Rural (reference  urban) 0.94 0.49 0.79 0.0001
SES 1.06 0.02 0.93 0.0001
Stage II 1.07 0.67 1.48 0.0001
Stage III 0.95 0.55 1.73 0.0001
Stage IV (reference  stage I) 1.03 0.72 0.88 0.01
a CT scan use, MRI use, and/or PET scan use.
b Bronchoscopy, mediastinoscopy, and/or thoracoscopy.
SES, socioeconomic status; CT scan, computed tomography scan; MRI, magnetic
resonance imaging; PET scan, positron emission tomography scan; OR, odds ratio.
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to obtain a PET scan (OR  1.27, 95% CI: 1.02–1.58; p 
0.03), and stage IV had the highest odds of obtaining MRI
scan (OR  9.96, 95% CI: 6.53–15.2; p  0.0001), whereas
CT scan use was not significantly different based on stage.
Similarly, the odds of patients obtaining different inva-
sive staging procedures were evaluated and summarized in
Table 4. Similar to the results above for the use of noninva-
sive staging procedures by white and non-white patients, race
did not affect the likelihood of obtaining any individual
invasive staging procedure. Males were more likely to un-
dergo bronchoscopy (OR  1.21, 95% CI: 1.13–1.31; p 
0.001). Rural patients were less likely to obtain bronchoscopy
(OR  0.8, 95% CI: 0.72–0.89; p  0.001) or mediastinos-
copy (OR  0.7, 95% CI: 0.49–0.97; p  0.03) but more
likely to obtain thoracoscopy (OR  1.88, 95% CI: 1.05–
3.36; p  0.03). Higher SES was associated with the in-
creased likelihood of obtaining a mediastinoscopy, and con-
versely, bronchoscopy was more likely to be obtained in the
lower SES group. Stage III patients were more likely to
obtain a bronchoscopy (OR  1.71, 95% CI: 1.54–1.89; p 
0.0001), whereas stage II patients had the highest odds of
obtaining a mediastinoscopy (OR  1.72, 95% CI: 1.13–2.6;
p  0.01). Stage IV patients were the least likely to obtain
invasive staging, both individual and overall.
We note that the no association between race and the
likelihood of obtaining noninvasive (and similarly for inva-
sive) staging procedures remains unchanged when we ana-
lyzed the data with race categorized as white, black, and
other. That is, the odds of obtaining noninvasive (or invasive)
staging were not different between black and white patients
and between other and white patients (results not shown). In
addition, we performed a sensitivity analysis that included the
entire cohort of 13,762 patients, and the results remained
unchanged compared with the 12,395-patient study cohort
(results not shown).
Likelihood of Surgery and Survival of Staged
Patients
We examined the likelihood (odds) of receiving surgery
among staged patients stratified by noninvasive (N 11,044)
or invasive (N  5070) staging procedure use adjusted for
known confounders (Table 5). Analysis of the effect of race
categorized as white or non-white patients (Table 5) suggests
that non-white patients who underwent noninvasive staging
were less likely to undergo surgery compared with whites
(OR  0.78; 95% CI: 0.67–0.92; p  0.003). For non-white
patients who underwent invasive staging, the estimated odds
of surgery is also lower compared with whites, although the
results were not statistically significant (OR  0.88; p 
0.26). We further examined the relationship between race,
adjusted for known confounders, but with race further cate-
gorized as white, black, and other (Table 5). Black patients
who underwent noninvasive staging were substantially less
likely than white patients to undergo surgery (OR  0.60;
95% CI: 0.46–0.78; p  0.001), and this was similar for
black patients who underwent invasive staging (OR  0.63;
95% CI: 0.43–0.93; p  0.001). The “race other” group
was not different from the white race group.
We further examined the survival characteristics among
patients who underwent surgery. Based on univariate and
multivariate analysis, using Kaplan-Meier and Cox regres-
sion analysis, respectively, we found no difference in survival
between white and non-white patients. Specifically, among
noninvasively staged patients who underwent surgery, the
median survival was 3.7 and 3.8 years for white and non-
TABLE 3. Predictors of Undergoing Specific Noninvasive
Staging Procedures
PET Scan MRI CT Scan
OR p OR p OR p
Race
Nonwhite
(reference 
white)
0.98 0.72 0.8 0.06 1.05 0.5
Age 1 0.89 0.98 0.0001 1 0.47
Sex
Male
(reference 
female)
0.87 0.01 1.02 0.79 1.04 0.47
Residence
Rural
(reference 
urban)
0.87 0.08 0.87 0.29 1 0.99
SES 1.15 0.0001 1.02 0.6 1.04 0.08
Stage II 1.27 0.03 2.55 0.01 1.08 0.58
Stage III 0.55 0.0001 2.05 0.01 1.1 0.2
Stage IV
(reference 
stage I)
0.42 0.0001 9.96 0.0001 1.03 0.64
SES, socioeconomic status; CT scan, computed tomography scan; MRI, magnetic
resonance imaging; PET scan, positron emission tomography scan; OR, odds ratio.
TABLE 4. Predictors of Undergoing Invasive Staging
Procedures
Bronchoscopy Mediastinoscopy Thoracoscopy
OR p OR p OR p
Race
Nonwhite
(reference 
white)
0.96 0.41 0.85 0.24 0.95 0.87
Age 0.99 0.0001 0.98 0.0001 0.98 0.06
Sex
Male
(reference 
female)
1.21 0.0001 1.22 0.06 1.16 0.55
Residence
Rural
(reference 
urban)
0.8 0.0001 0.7 0.03 1.88 0.03
SES 0.93 0.0001 1.09 0.05 1.01 0.95
Stage II 1.47 0.0001 1.72 0.01 0.44 0.27
Stage III 1.71 0.0001 1.34 0.03 0.82 0.51
Stage IV
(reference 
stage I)
0.92 0.09 0.44 0.0001 0.4 0.01
OR, odds ratio.
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white groups, respectively (p  0.98). Similarly, for inva-
sively staged patients, the median survival was 3.4 and 3
years (p  0.3) for white and non-white groups, respectively.
These results remain unchanged after adjusting for confound-
ing covariates using Cox regression analysis: the adjusted
hazard ratio for non-white patients was 0.95 (95% CI: 0.83–
1.09; p  0.45) for patients undergoing noninvasive staging.
The result was similar for patients undergoing invasive stag-
ing procedure: the adjusted hazard ratio for non-white was
1.03 (95% CI: 0.86–1.23; p  0.79).
DISCUSSION
In this analysis of patients reported to the CCR from the
Sacramento region in Northern California, we found no
detectable differences in staging procedures between white
and non-white NSCLC patients. Noninvasive staging proce-
dure use was similar and not influenced by race, age, sex,
residence, or stage on initial presentation. There was a small
but real difference seen in PET scan use based on SES, where
the higher SES group had an increased likelihood of obtain-
ing a PET scan. Obtaining invasive staging procedures such
as bronchoscopy, mediastinoscopy, or thoracoscopy was not
influenced by race; however, all other variables evaluated,
including age, sex, residence, SES, and stage on presentation,
seemed to be independent predictors for the use of invasive
staging. Although staging seemed to be similar between the
two groups, there was a nonsignificant difference between
white and non-white patients and the likelihood of obtaining
operative therapy. This difference became more apparent and
statistically significant when black patients were compared
with white patients, and the difference was not seen between
white and other non-white patients. The most powerful neg-
ative predictors of surgery was stage III and IV disease and
race, while SES and age were also found to be significant
independent factors. Survival was similar for those who
underwent surgery. Our data suggest that staging procedure
usage does not seem to be contributing to the striking differ-
ences in operative rates between the two groups.
To our knowledge, this is the first study that looked at
both invasive and noninvasive staging patterns for NSCLC,
including PET scan use, stratified by race. Our findings are in
contrast to prior work by Lathan et al., which reported a
difference in invasive staging use between black and white
patients. There are many possible explanations for why our
results differed from the study by Lathan et al. First, there
may be some regional differences for staging of NSCLC. Our
analysis focused on one region of California, which may
differ from national patterns for lung cancer staging. In
addition, Lathan et al. looked at Medicare-eligible patients
only, whereas the CCR looked at all NSCLC diagnosed
during the 10-year period evaluated. However, our data are
consistent with Lathan et al. and several other studies that
uniformly show lower surgical rates for black patients.9–12,24,25
Many have speculated different reasons for this racial
disparity. One proposed explanation is that black patients
may not have access to quality subspecialty care necessary
for optimal care. There is some evidence that physicians who
treat black patients are more likely to report that they have
difficulties getting access to high-quality subspecialists, di-
agnostic imaging, and nonemergency admissions to the hos-
pital.26 Cykert et al.27 identified that lack of regular source of
care along with more comorbid illnesses was found to be a
significant factor in explaining the lower surgery rates in
black patients. Other studies have suggested that physician–
patient interactions may be important. A study of SEER
Medicare database showed that despite a recommendation for
surgery, there was a lower resection rate in black patients
compared with whites.24 Cykert et al.27 also found that for all
patients, negative perceptions of patient–physician commu-
nication along with negative perceptions of 1-year prognosis
postsurgery were strongly associated with decisions to forgo
surgery. Mistrust in physicians may be another reason for the
lower rates of surgery in blacks. A study conducted at a
Southern Veterans Affairs center suggested that black pa-
tients reported lower postvisit trust in physicians compared
TABLE 5. Likelihood of Surgery Among Staged Patients
Noninvasive
Staging Invasive Staging
OR p OR p
Race: white/nonwhite
Race
Black 0.6 0.001 0.63 0.02
Other 0.89 0.2 1.02 0.89
(reference  white)
Age 0.95 0.001 0.96 0.001
Sex
Male
(reference  female)
0.96 0.5 1.06 0.52
Residence
Rural
(reference  urban)
1.05 0.57 0.96 0.78
SES 1.19 0.001 1.17 0.001
Stage II 0.96 0.73 0.86 0.39
Stage III 0.06 0.001 0.05 0.001
Stage IV
(reference  stage I)
0.01 0.001 0.01 0.001
Race: white/black
Race
Black
(reference  white)
0.60 0.001 0.63 0.02
Age 0.89 0.2 1.02 0.89
Sex
Male
(reference  female)
0.95 0.52 1.06 0.54
Residence
Rural
(reference  urban)
1.04 0.63 0.96 0.74
SES 1.18 0.001 1.17 0.001
Stage II 0.96 0.77 0.87 0.43
Stage III 0.06 0.001 0.05 0.001
Stage IV
(reference  stage I)
0.01 0.001 0.01 0.001
SES, socioeconomic status; OR, odds ratio.
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with white patients and that black patients judged physician
communications to be less supportive, less partnering, and
less informative.28 Different belief systems based on race
have also been reported. A study by Margolis et al.29 found
38% of patients, of whom 61% were black patients, stated
that they believed air exposure at time of surgery caused
tumor spread. In addition, 19% of black patients cited that
this belief was the reason for refusing surgery.
There are some limitations to our study. The CCR did
not collect information about comorbidities or performance
status at time of presentation, which influences the recom-
mendation for surgery. It is certainly possible that black
patients had more comorbidities or a lower performance
status at the time of presentation compared with white pa-
tients, which could partly explain the lower rates of surgery.
Blackstock et al.30 reported an analysis of Cancer and Leu-
kemia Group B clinical trials data, which suggested that the
survival rates of black patients were inferior compared with
non-black patients; however, the effect of race disappeared
after adjustment for performance status and weight loss. SES
was based on the address of the patient at time of diagnosis
and census data. It is unclear whether community-based SES
determination is comparable with individual-based SES. In-
surance status was not included in our model. Instead, we
used SES as an indirect surrogate for this variable. Mulligan
et al.4 examined patients from the VA system and found that
the racial disparities disappeared when access to care was
universal for the entire group, which suggests that insurance
status may have a big impact on outcome. SES and insurance
status captures similar information but are likely not inter-
changeable. We also did not examine smoking status in our
analysis. There have been conflicting reports whether smok-
ing affects treatment outcome. Although some reports have
found a relationship between smoking status and out-
comes,31–33 others have not.34 Another potential limitation of
the reported results is the effect of misclassification of race.
This misclassification may lead to attenuation of effect esti-
mates, leading to null results. Finally, our study looked at the
CCR data reported by the Sacramento region and therefore
may not be fully generalizable to other regions in the country.
In conclusion, we were able to show that unlike prior
reports, race was not a significant predictor in obtaining
noninvasive or invasive staging procedures for lung cancer,
and other factors such as SES may be more relevant. Even
though the staging work-up for NSCLC seemed to be similar
based on race, there was a significant difference in surgical
rates between white and black patients, confirming other
previously published studies. More research on health care
factors and physician–patient interactions, which may influ-
ence the disparities seen in surgical rates, is warranted.
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